Edition:
United States

Checkpoint Therapeutics Inc (CKPT.OQ)

CKPT.OQ on NASDAQ Stock Exchange Capital Market

3.03USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$3.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,631
52-wk High
$5.16
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Checkpoint Therapeutics Q1 Loss Per Share $0.18
Thursday, 9 May 2019 05:00pm EDT 

May 9 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q1 LOSS PER SHARE $0.18.BELIEVES ITS CASH OTHERS WILL BE SUFFICIENT TO FUND ITS ANTICIPATED OPERATING CASH REQUIREMENTS FOR AT LEAST 12 MONTHS.  Full Article

Checkpoint Therapeutics Announces Positive Interim Clinical Results Of Anti-Pd-L1 Antibody Cosibelimab
Wednesday, 1 May 2019 07:30am EDT 

May 1 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS ANNOUNCES POSITIVE INTERIM CLINICAL RESULTS OF ANTI-PD-L1 ANTIBODY COSIBELIMAB.CHECKPOINT THERAPEUTICS INC - WELL-TOLERATED SAFETY PROFILE.CHECKPOINT THERAPEUTICS INC - >40% OBJECTIVE RESPONSE RATES OBSERVED IN FIRST-LINE NON-SMALL CELL LUNG CANCER AND CUTANEOUS SQUAMOUS CELL CARCINOMA.CHECKPOINT THERAPEUTICS INC - ENROLLMENT ONGOING IN EXPANSION COHORTS INTENDED TO SUPPORT POTENTIAL BLA SUBMISSIONS.  Full Article

Checkpoint Therapeutics Says Cash & Cash Equivalents Totaled $22.0 Mln As Of Dec 31, 2018 vs $19.2 Mln As Of Dec 31, 2017
Friday, 15 Mar 2019 07:30am EDT 

March 15 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.CHECKPOINT THERAPEUTICS - AS OF DECEMBER 31, 2018, CO'S CASH AND CASH EQUIVALENTS TOTALED $22.0 MILLION, COMPARED TO $19.2 MILLION AT DECEMBER 31, 2017.  Full Article

Checkpoint Therapeutics reports third quarter results
Friday, 2 Nov 2018 08:00am EDT 

Nov 2 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.32.AS OF SEPT 30 CO'S CASH AND CASH EQUIVALENTS TOTALED $29.6 MILLION, VERSUS $19.2 MILLION AT DEC 31, 2017.  Full Article

Checkpoint Therapeutics Announces Encouraging Safety And Efficacy Data From Phase 1/2 Clinical Trial Of Egfr Inhibitor Ck-101
Thursday, 6 Sep 2018 07:30am EDT 

Sept 6 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA FROM PHASE 1/2 CLINICAL TRIAL OF EGFR INHIBITOR CK-101.CHECKPOINT THERAPEUTICS INC - PHASE 3 TRIAL IN TREATMENT-NAÏVE EGFR MUTATION-POSITIVE NSCLC PATIENTS TARGETED TO COMMENCE IN 2019.CHECKPOINT THERAPEUTICS INC - EGFR INHIBITOR CK-101 WELL-TOLERATED WITH UNREMARKABLE SAFETY PROFILE.  Full Article

Checkpoint Therapeutics Reports Q4 Results
Thursday, 15 Mar 2018 04:05pm EDT 

March 15 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.CHECKPOINT THERAPEUTICS INC - ‍AS OF DECEMBER 31, 2017, CHECKPOINT'S CASH AND CASH EQUIVALENTS TOTALED $19.2 MILLION​.  Full Article

Checkpoint Therapeutics Announces Pricing Of Public Offering Of Common Stock
Thursday, 8 Mar 2018 09:00am EST 

March 8 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING OF 4.60 MILLION COMMON SHARES PRICED AT $4.35PER SHARE.  Full Article

Checkpoint Therapeutics files for mixed shelf offering of up to $100 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:44pm EST 

Nov 9 (Reuters) - Checkpoint Therapeutics Inc :Checkpoint Therapeutics Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Checkpoint Therapeutics receives orphan drug designation for CK-101
Monday, 11 Sep 2017 08:30am EDT 

Sept 11 (Reuters) - Checkpoint Therapeutics Inc ::Checkpoint Therapeutics receives orphan drug designation for ck-101 for the treatment of egfr mutation-positive non-small cell lung cancer.Checkpoint Therapeutics Inc - ‍ck-101 is currently being studied in phase 1 dose-escalation portion of a phase 1/2 clinical study​.  Full Article